Global Genome-Based Drug Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
LPI (LP Information)' newest research report, the “Genome-Based Drug Industry Forecast” looks at past sales and reviews total world Genome-Based Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Genome-Based Drug sales for 2023 through 2029. With Genome-Based Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Genome-Based Drug industry.
This Insight Report provides a comprehensive analysis of the global Genome-Based Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Genome-Based Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Genome-Based Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Genome-Based Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Genome-Based Drug.
The global Genome-Based Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Genome-Based Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Genome-Based Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Genome-Based Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Genome-Based Drug players cover Sandoz International, Teva pharmaceutical industries, Mylan, 3SBio, Shanghai Fosun Pharmaceutical, Tonghua Dongbao Pharmaceutical, Biocon, Reliance Life Sciences and Probiomed, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Genome-Based Drug market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Genome-Based Drug market?
What factors are driving Genome-Based Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Genome-Based Drug market opportunities vary by end market size?
How does Genome-Based Drug break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Genome-Based Drug Industry Forecast” looks at past sales and reviews total world Genome-Based Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Genome-Based Drug sales for 2023 through 2029. With Genome-Based Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Genome-Based Drug industry.
This Insight Report provides a comprehensive analysis of the global Genome-Based Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Genome-Based Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Genome-Based Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Genome-Based Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Genome-Based Drug.
The global Genome-Based Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Genome-Based Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Genome-Based Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Genome-Based Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Genome-Based Drug players cover Sandoz International, Teva pharmaceutical industries, Mylan, 3SBio, Shanghai Fosun Pharmaceutical, Tonghua Dongbao Pharmaceutical, Biocon, Reliance Life Sciences and Probiomed, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Genome-Based Drug market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Insulin
- Growth Hormone
- Monoclonal Antibody
- Other
- Hospital
- Pharmaceutical Factory
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sandoz International
- Teva pharmaceutical industries
- Mylan
- 3SBio
- Shanghai Fosun Pharmaceutical
- Tonghua Dongbao Pharmaceutical
- Biocon
- Reliance Life Sciences
- Probiomed
- Biosidus
- AMEGA Biotech
- Celltrion
- LG Life Science
- Dong-A Pharmaceutical
What is the 10-year outlook for the global Genome-Based Drug market?
What factors are driving Genome-Based Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Genome-Based Drug market opportunities vary by end market size?
How does Genome-Based Drug break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Genome-Based Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Genome-Based Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Genome-Based Drug by Country/Region, 2018, 2022 & 2029
2.2 Genome-Based Drug Segment by Type
2.2.1 Insulin
2.2.2 Growth Hormone
2.2.3 Monoclonal Antibody
2.2.4 Other
2.3 Genome-Based Drug Sales by Type
2.3.1 Global Genome-Based Drug Sales Market Share by Type (2018-2023)
2.3.2 Global Genome-Based Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global Genome-Based Drug Sale Price by Type (2018-2023)
2.4 Genome-Based Drug Segment by Application
2.4.1 Hospital
2.4.2 Pharmaceutical Factory
2.4.3 Other
2.5 Genome-Based Drug Sales by Application
2.5.1 Global Genome-Based Drug Sale Market Share by Application (2018-2023)
2.5.2 Global Genome-Based Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global Genome-Based Drug Sale Price by Application (2018-2023)
3 GLOBAL GENOME-BASED DRUG BY COMPANY
3.1 Global Genome-Based Drug Breakdown Data by Company
3.1.1 Global Genome-Based Drug Annual Sales by Company (2018-2023)
3.1.2 Global Genome-Based Drug Sales Market Share by Company (2018-2023)
3.2 Global Genome-Based Drug Annual Revenue by Company (2018-2023)
3.2.1 Global Genome-Based Drug Revenue by Company (2018-2023)
3.2.2 Global Genome-Based Drug Revenue Market Share by Company (2018-2023)
3.3 Global Genome-Based Drug Sale Price by Company
3.4 Key Manufacturers Genome-Based Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Genome-Based Drug Product Location Distribution
3.4.2 Players Genome-Based Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR GENOME-BASED DRUG BY GEOGRAPHIC REGION
4.1 World Historic Genome-Based Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global Genome-Based Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Genome-Based Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Genome-Based Drug Market Size by Country/Region (2018-2023)
4.2.1 Global Genome-Based Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global Genome-Based Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas Genome-Based Drug Sales Growth
4.4 APAC Genome-Based Drug Sales Growth
4.5 Europe Genome-Based Drug Sales Growth
4.6 Middle East & Africa Genome-Based Drug Sales Growth
5 AMERICAS
5.1 Americas Genome-Based Drug Sales by Country
5.1.1 Americas Genome-Based Drug Sales by Country (2018-2023)
5.1.2 Americas Genome-Based Drug Revenue by Country (2018-2023)
5.2 Americas Genome-Based Drug Sales by Type
5.3 Americas Genome-Based Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Genome-Based Drug Sales by Region
6.1.1 APAC Genome-Based Drug Sales by Region (2018-2023)
6.1.2 APAC Genome-Based Drug Revenue by Region (2018-2023)
6.2 APAC Genome-Based Drug Sales by Type
6.3 APAC Genome-Based Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Genome-Based Drug by Country
7.1.1 Europe Genome-Based Drug Sales by Country (2018-2023)
7.1.2 Europe Genome-Based Drug Revenue by Country (2018-2023)
7.2 Europe Genome-Based Drug Sales by Type
7.3 Europe Genome-Based Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Genome-Based Drug by Country
8.1.1 Middle East & Africa Genome-Based Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa Genome-Based Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa Genome-Based Drug Sales by Type
8.3 Middle East & Africa Genome-Based Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Genome-Based Drug
10.3 Manufacturing Process Analysis of Genome-Based Drug
10.4 Industry Chain Structure of Genome-Based Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Genome-Based Drug Distributors
11.3 Genome-Based Drug Customer
12 WORLD FORECAST REVIEW FOR GENOME-BASED DRUG BY GEOGRAPHIC REGION
12.1 Global Genome-Based Drug Market Size Forecast by Region
12.1.1 Global Genome-Based Drug Forecast by Region (2024-2029)
12.1.2 Global Genome-Based Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Genome-Based Drug Forecast by Type
12.7 Global Genome-Based Drug Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Sandoz International
13.1.1 Sandoz International Company Information
13.1.2 Sandoz International Genome-Based Drug Product Portfolios and Specifications
13.1.3 Sandoz International Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Sandoz International Main Business Overview
13.1.5 Sandoz International Latest Developments
13.2 Teva pharmaceutical industries
13.2.1 Teva pharmaceutical industries Company Information
13.2.2 Teva pharmaceutical industries Genome-Based Drug Product Portfolios and Specifications
13.2.3 Teva pharmaceutical industries Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Teva pharmaceutical industries Main Business Overview
13.2.5 Teva pharmaceutical industries Latest Developments
13.3 Mylan
13.3.1 Mylan Company Information
13.3.2 Mylan Genome-Based Drug Product Portfolios and Specifications
13.3.3 Mylan Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Mylan Main Business Overview
13.3.5 Mylan Latest Developments
13.4 3SBio
13.4.1 3SBio Company Information
13.4.2 3SBio Genome-Based Drug Product Portfolios and Specifications
13.4.3 3SBio Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 3SBio Main Business Overview
13.4.5 3SBio Latest Developments
13.5 Shanghai Fosun Pharmaceutical
13.5.1 Shanghai Fosun Pharmaceutical Company Information
13.5.2 Shanghai Fosun Pharmaceutical Genome-Based Drug Product Portfolios and Specifications
13.5.3 Shanghai Fosun Pharmaceutical Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Shanghai Fosun Pharmaceutical Main Business Overview
13.5.5 Shanghai Fosun Pharmaceutical Latest Developments
13.6 Tonghua Dongbao Pharmaceutical
13.6.1 Tonghua Dongbao Pharmaceutical Company Information
13.6.2 Tonghua Dongbao Pharmaceutical Genome-Based Drug Product Portfolios and Specifications
13.6.3 Tonghua Dongbao Pharmaceutical Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Tonghua Dongbao Pharmaceutical Main Business Overview
13.6.5 Tonghua Dongbao Pharmaceutical Latest Developments
13.7 Biocon
13.7.1 Biocon Company Information
13.7.2 Biocon Genome-Based Drug Product Portfolios and Specifications
13.7.3 Biocon Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Biocon Main Business Overview
13.7.5 Biocon Latest Developments
13.8 Reliance Life Sciences
13.8.1 Reliance Life Sciences Company Information
13.8.2 Reliance Life Sciences Genome-Based Drug Product Portfolios and Specifications
13.8.3 Reliance Life Sciences Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Reliance Life Sciences Main Business Overview
13.8.5 Reliance Life Sciences Latest Developments
13.9 Probiomed
13.9.1 Probiomed Company Information
13.9.2 Probiomed Genome-Based Drug Product Portfolios and Specifications
13.9.3 Probiomed Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Probiomed Main Business Overview
13.9.5 Probiomed Latest Developments
13.10 Biosidus
13.10.1 Biosidus Company Information
13.10.2 Biosidus Genome-Based Drug Product Portfolios and Specifications
13.10.3 Biosidus Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Biosidus Main Business Overview
13.10.5 Biosidus Latest Developments
13.11 AMEGA Biotech
13.11.1 AMEGA Biotech Company Information
13.11.2 AMEGA Biotech Genome-Based Drug Product Portfolios and Specifications
13.11.3 AMEGA Biotech Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 AMEGA Biotech Main Business Overview
13.11.5 AMEGA Biotech Latest Developments
13.12 Celltrion
13.12.1 Celltrion Company Information
13.12.2 Celltrion Genome-Based Drug Product Portfolios and Specifications
13.12.3 Celltrion Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Celltrion Main Business Overview
13.12.5 Celltrion Latest Developments
13.13 LG Life Science
13.13.1 LG Life Science Company Information
13.13.2 LG Life Science Genome-Based Drug Product Portfolios and Specifications
13.13.3 LG Life Science Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 LG Life Science Main Business Overview
13.13.5 LG Life Science Latest Developments
13.14 Dong-A Pharmaceutical
13.14.1 Dong-A Pharmaceutical Company Information
13.14.2 Dong-A Pharmaceutical Genome-Based Drug Product Portfolios and Specifications
13.14.3 Dong-A Pharmaceutical Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Dong-A Pharmaceutical Main Business Overview
13.14.5 Dong-A Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Genome-Based Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Genome-Based Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Genome-Based Drug by Country/Region, 2018, 2022 & 2029
2.2 Genome-Based Drug Segment by Type
2.2.1 Insulin
2.2.2 Growth Hormone
2.2.3 Monoclonal Antibody
2.2.4 Other
2.3 Genome-Based Drug Sales by Type
2.3.1 Global Genome-Based Drug Sales Market Share by Type (2018-2023)
2.3.2 Global Genome-Based Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global Genome-Based Drug Sale Price by Type (2018-2023)
2.4 Genome-Based Drug Segment by Application
2.4.1 Hospital
2.4.2 Pharmaceutical Factory
2.4.3 Other
2.5 Genome-Based Drug Sales by Application
2.5.1 Global Genome-Based Drug Sale Market Share by Application (2018-2023)
2.5.2 Global Genome-Based Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global Genome-Based Drug Sale Price by Application (2018-2023)
3 GLOBAL GENOME-BASED DRUG BY COMPANY
3.1 Global Genome-Based Drug Breakdown Data by Company
3.1.1 Global Genome-Based Drug Annual Sales by Company (2018-2023)
3.1.2 Global Genome-Based Drug Sales Market Share by Company (2018-2023)
3.2 Global Genome-Based Drug Annual Revenue by Company (2018-2023)
3.2.1 Global Genome-Based Drug Revenue by Company (2018-2023)
3.2.2 Global Genome-Based Drug Revenue Market Share by Company (2018-2023)
3.3 Global Genome-Based Drug Sale Price by Company
3.4 Key Manufacturers Genome-Based Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Genome-Based Drug Product Location Distribution
3.4.2 Players Genome-Based Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR GENOME-BASED DRUG BY GEOGRAPHIC REGION
4.1 World Historic Genome-Based Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global Genome-Based Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Genome-Based Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Genome-Based Drug Market Size by Country/Region (2018-2023)
4.2.1 Global Genome-Based Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global Genome-Based Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas Genome-Based Drug Sales Growth
4.4 APAC Genome-Based Drug Sales Growth
4.5 Europe Genome-Based Drug Sales Growth
4.6 Middle East & Africa Genome-Based Drug Sales Growth
5 AMERICAS
5.1 Americas Genome-Based Drug Sales by Country
5.1.1 Americas Genome-Based Drug Sales by Country (2018-2023)
5.1.2 Americas Genome-Based Drug Revenue by Country (2018-2023)
5.2 Americas Genome-Based Drug Sales by Type
5.3 Americas Genome-Based Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Genome-Based Drug Sales by Region
6.1.1 APAC Genome-Based Drug Sales by Region (2018-2023)
6.1.2 APAC Genome-Based Drug Revenue by Region (2018-2023)
6.2 APAC Genome-Based Drug Sales by Type
6.3 APAC Genome-Based Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Genome-Based Drug by Country
7.1.1 Europe Genome-Based Drug Sales by Country (2018-2023)
7.1.2 Europe Genome-Based Drug Revenue by Country (2018-2023)
7.2 Europe Genome-Based Drug Sales by Type
7.3 Europe Genome-Based Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Genome-Based Drug by Country
8.1.1 Middle East & Africa Genome-Based Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa Genome-Based Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa Genome-Based Drug Sales by Type
8.3 Middle East & Africa Genome-Based Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Genome-Based Drug
10.3 Manufacturing Process Analysis of Genome-Based Drug
10.4 Industry Chain Structure of Genome-Based Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Genome-Based Drug Distributors
11.3 Genome-Based Drug Customer
12 WORLD FORECAST REVIEW FOR GENOME-BASED DRUG BY GEOGRAPHIC REGION
12.1 Global Genome-Based Drug Market Size Forecast by Region
12.1.1 Global Genome-Based Drug Forecast by Region (2024-2029)
12.1.2 Global Genome-Based Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Genome-Based Drug Forecast by Type
12.7 Global Genome-Based Drug Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Sandoz International
13.1.1 Sandoz International Company Information
13.1.2 Sandoz International Genome-Based Drug Product Portfolios and Specifications
13.1.3 Sandoz International Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Sandoz International Main Business Overview
13.1.5 Sandoz International Latest Developments
13.2 Teva pharmaceutical industries
13.2.1 Teva pharmaceutical industries Company Information
13.2.2 Teva pharmaceutical industries Genome-Based Drug Product Portfolios and Specifications
13.2.3 Teva pharmaceutical industries Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Teva pharmaceutical industries Main Business Overview
13.2.5 Teva pharmaceutical industries Latest Developments
13.3 Mylan
13.3.1 Mylan Company Information
13.3.2 Mylan Genome-Based Drug Product Portfolios and Specifications
13.3.3 Mylan Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Mylan Main Business Overview
13.3.5 Mylan Latest Developments
13.4 3SBio
13.4.1 3SBio Company Information
13.4.2 3SBio Genome-Based Drug Product Portfolios and Specifications
13.4.3 3SBio Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 3SBio Main Business Overview
13.4.5 3SBio Latest Developments
13.5 Shanghai Fosun Pharmaceutical
13.5.1 Shanghai Fosun Pharmaceutical Company Information
13.5.2 Shanghai Fosun Pharmaceutical Genome-Based Drug Product Portfolios and Specifications
13.5.3 Shanghai Fosun Pharmaceutical Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Shanghai Fosun Pharmaceutical Main Business Overview
13.5.5 Shanghai Fosun Pharmaceutical Latest Developments
13.6 Tonghua Dongbao Pharmaceutical
13.6.1 Tonghua Dongbao Pharmaceutical Company Information
13.6.2 Tonghua Dongbao Pharmaceutical Genome-Based Drug Product Portfolios and Specifications
13.6.3 Tonghua Dongbao Pharmaceutical Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Tonghua Dongbao Pharmaceutical Main Business Overview
13.6.5 Tonghua Dongbao Pharmaceutical Latest Developments
13.7 Biocon
13.7.1 Biocon Company Information
13.7.2 Biocon Genome-Based Drug Product Portfolios and Specifications
13.7.3 Biocon Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Biocon Main Business Overview
13.7.5 Biocon Latest Developments
13.8 Reliance Life Sciences
13.8.1 Reliance Life Sciences Company Information
13.8.2 Reliance Life Sciences Genome-Based Drug Product Portfolios and Specifications
13.8.3 Reliance Life Sciences Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Reliance Life Sciences Main Business Overview
13.8.5 Reliance Life Sciences Latest Developments
13.9 Probiomed
13.9.1 Probiomed Company Information
13.9.2 Probiomed Genome-Based Drug Product Portfolios and Specifications
13.9.3 Probiomed Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Probiomed Main Business Overview
13.9.5 Probiomed Latest Developments
13.10 Biosidus
13.10.1 Biosidus Company Information
13.10.2 Biosidus Genome-Based Drug Product Portfolios and Specifications
13.10.3 Biosidus Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Biosidus Main Business Overview
13.10.5 Biosidus Latest Developments
13.11 AMEGA Biotech
13.11.1 AMEGA Biotech Company Information
13.11.2 AMEGA Biotech Genome-Based Drug Product Portfolios and Specifications
13.11.3 AMEGA Biotech Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 AMEGA Biotech Main Business Overview
13.11.5 AMEGA Biotech Latest Developments
13.12 Celltrion
13.12.1 Celltrion Company Information
13.12.2 Celltrion Genome-Based Drug Product Portfolios and Specifications
13.12.3 Celltrion Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Celltrion Main Business Overview
13.12.5 Celltrion Latest Developments
13.13 LG Life Science
13.13.1 LG Life Science Company Information
13.13.2 LG Life Science Genome-Based Drug Product Portfolios and Specifications
13.13.3 LG Life Science Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 LG Life Science Main Business Overview
13.13.5 LG Life Science Latest Developments
13.14 Dong-A Pharmaceutical
13.14.1 Dong-A Pharmaceutical Company Information
13.14.2 Dong-A Pharmaceutical Genome-Based Drug Product Portfolios and Specifications
13.14.3 Dong-A Pharmaceutical Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Dong-A Pharmaceutical Main Business Overview
13.14.5 Dong-A Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Genome-Based Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Genome-Based Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Insulin
Table 4. Major Players of Growth Hormone
Table 5. Major Players of Monoclonal Antibody
Table 6. Major Players of Other
Table 7. Global Genome-Based Drug Sales by Type (2018-2023) & (Kiloton)
Table 8. Global Genome-Based Drug Sales Market Share by Type (2018-2023)
Table 9. Global Genome-Based Drug Revenue by Type (2018-2023) & ($ million)
Table 10. Global Genome-Based Drug Revenue Market Share by Type (2018-2023)
Table 11. Global Genome-Based Drug Sale Price by Type (2018-2023) & (US$/Ton)
Table 12. Global Genome-Based Drug Sales by Application (2018-2023) & (Kiloton)
Table 13. Global Genome-Based Drug Sales Market Share by Application (2018-2023)
Table 14. Global Genome-Based Drug Revenue by Application (2018-2023)
Table 15. Global Genome-Based Drug Revenue Market Share by Application (2018-2023)
Table 16. Global Genome-Based Drug Sale Price by Application (2018-2023) & (US$/Ton)
Table 17. Global Genome-Based Drug Sales by Company (2018-2023) & (Kiloton)
Table 18. Global Genome-Based Drug Sales Market Share by Company (2018-2023)
Table 19. Global Genome-Based Drug Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Genome-Based Drug Revenue Market Share by Company (2018-2023)
Table 21. Global Genome-Based Drug Sale Price by Company (2018-2023) & (US$/Ton)
Table 22. Key Manufacturers Genome-Based Drug Producing Area Distribution and Sales Area
Table 23. Players Genome-Based Drug Products Offered
Table 24. Genome-Based Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Genome-Based Drug Sales by Geographic Region (2018-2023) & (Kiloton)
Table 28. Global Genome-Based Drug Sales Market Share Geographic Region (2018-2023)
Table 29. Global Genome-Based Drug Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Genome-Based Drug Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Genome-Based Drug Sales by Country/Region (2018-2023) & (Kiloton)
Table 32. Global Genome-Based Drug Sales Market Share by Country/Region (2018-2023)
Table 33. Global Genome-Based Drug Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Genome-Based Drug Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Genome-Based Drug Sales by Country (2018-2023) & (Kiloton)
Table 36. Americas Genome-Based Drug Sales Market Share by Country (2018-2023)
Table 37. Americas Genome-Based Drug Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Genome-Based Drug Revenue Market Share by Country (2018-2023)
Table 39. Americas Genome-Based Drug Sales by Type (2018-2023) & (Kiloton)
Table 40. Americas Genome-Based Drug Sales by Application (2018-2023) & (Kiloton)
Table 41. APAC Genome-Based Drug Sales by Region (2018-2023) & (Kiloton)
Table 42. APAC Genome-Based Drug Sales Market Share by Region (2018-2023)
Table 43. APAC Genome-Based Drug Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Genome-Based Drug Revenue Market Share by Region (2018-2023)
Table 45. APAC Genome-Based Drug Sales by Type (2018-2023) & (Kiloton)
Table 46. APAC Genome-Based Drug Sales by Application (2018-2023) & (Kiloton)
Table 47. Europe Genome-Based Drug Sales by Country (2018-2023) & (Kiloton)
Table 48. Europe Genome-Based Drug Sales Market Share by Country (2018-2023)
Table 49. Europe Genome-Based Drug Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Genome-Based Drug Revenue Market Share by Country (2018-2023)
Table 51. Europe Genome-Based Drug Sales by Type (2018-2023) & (Kiloton)
Table 52. Europe Genome-Based Drug Sales by Application (2018-2023) & (Kiloton)
Table 53. Middle East & Africa Genome-Based Drug Sales by Country (2018-2023) & (Kiloton)
Table 54. Middle East & Africa Genome-Based Drug Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Genome-Based Drug Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Genome-Based Drug Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Genome-Based Drug Sales by Type (2018-2023) & (Kiloton)
Table 58. Middle East & Africa Genome-Based Drug Sales by Application (2018-2023) & (Kiloton)
Table 59. Key Market Drivers & Growth Opportunities of Genome-Based Drug
Table 60. Key Market Challenges & Risks of Genome-Based Drug
Table 61. Key Industry Trends of Genome-Based Drug
Table 62. Genome-Based Drug Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Genome-Based Drug Distributors List
Table 65. Genome-Based Drug Customer List
Table 66. Global Genome-Based Drug Sales Forecast by Region (2024-2029) & (Kiloton)
Table 67. Global Genome-Based Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Genome-Based Drug Sales Forecast by Country (2024-2029) & (Kiloton)
Table 69. Americas Genome-Based Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Genome-Based Drug Sales Forecast by Region (2024-2029) & (Kiloton)
Table 71. APAC Genome-Based Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Genome-Based Drug Sales Forecast by Country (2024-2029) & (Kiloton)
Table 73. Europe Genome-Based Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Genome-Based Drug Sales Forecast by Country (2024-2029) & (Kiloton)
Table 75. Middle East & Africa Genome-Based Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Genome-Based Drug Sales Forecast by Type (2024-2029) & (Kiloton)
Table 77. Global Genome-Based Drug Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Genome-Based Drug Sales Forecast by Application (2024-2029) & (Kiloton)
Table 79. Global Genome-Based Drug Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Sandoz International Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. Sandoz International Genome-Based Drug Product Portfolios and Specifications
Table 82. Sandoz International Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 83. Sandoz International Main Business
Table 84. Sandoz International Latest Developments
Table 85. Teva pharmaceutical industries Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. Teva pharmaceutical industries Genome-Based Drug Product Portfolios and Specifications
Table 87. Teva pharmaceutical industries Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 88. Teva pharmaceutical industries Main Business
Table 89. Teva pharmaceutical industries Latest Developments
Table 90. Mylan Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. Mylan Genome-Based Drug Product Portfolios and Specifications
Table 92. Mylan Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 93. Mylan Main Business
Table 94. Mylan Latest Developments
Table 95. 3SBio Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. 3SBio Genome-Based Drug Product Portfolios and Specifications
Table 97. 3SBio Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 98. 3SBio Main Business
Table 99. 3SBio Latest Developments
Table 100. Shanghai Fosun Pharmaceutical Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. Shanghai Fosun Pharmaceutical Genome-Based Drug Product Portfolios and Specifications
Table 102. Shanghai Fosun Pharmaceutical Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 103. Shanghai Fosun Pharmaceutical Main Business
Table 104. Shanghai Fosun Pharmaceutical Latest Developments
Table 105. Tonghua Dongbao Pharmaceutical Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. Tonghua Dongbao Pharmaceutical Genome-Based Drug Product Portfolios and Specifications
Table 107. Tonghua Dongbao Pharmaceutical Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 108. Tonghua Dongbao Pharmaceutical Main Business
Table 109. Tonghua Dongbao Pharmaceutical Latest Developments
Table 110. Biocon Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Biocon Genome-Based Drug Product Portfolios and Specifications
Table 112. Biocon Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 113. Biocon Main Business
Table 114. Biocon Latest Developments
Table 115. Reliance Life Sciences Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. Reliance Life Sciences Genome-Based Drug Product Portfolios and Specifications
Table 117. Reliance Life Sciences Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 118. Reliance Life Sciences Main Business
Table 119. Reliance Life Sciences Latest Developments
Table 120. Probiomed Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 121. Probiomed Genome-Based Drug Product Portfolios and Specifications
Table 122. Probiomed Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 123. Probiomed Main Business
Table 124. Probiomed Latest Developments
Table 125. Biosidus Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 126. Biosidus Genome-Based Drug Product Portfolios and Specifications
Table 127. Biosidus Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 128. Biosidus Main Business
Table 129. Biosidus Latest Developments
Table 130. AMEGA Biotech Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 131. AMEGA Biotech Genome-Based Drug Product Portfolios and Specifications
Table 132. AMEGA Biotech Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 133. AMEGA Biotech Main Business
Table 134. AMEGA Biotech Latest Developments
Table 135. Celltrion Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 136. Celltrion Genome-Based Drug Product Portfolios and Specifications
Table 137. Celltrion Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 138. Celltrion Main Business
Table 139. Celltrion Latest Developments
Table 140. LG Life Science Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 141. LG Life Science Genome-Based Drug Product Portfolios and Specifications
Table 142. LG Life Science Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 143. LG Life Science Main Business
Table 144. LG Life Science Latest Developments
Table 145. Dong-A Pharmaceutical Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 146. Dong-A Pharmaceutical Genome-Based Drug Product Portfolios and Specifications
Table 147. Dong-A Pharmaceutical Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 148. Dong-A Pharmaceutical Main Business
Table 149. Dong-A Pharmaceutical Latest Developments
Table 1. Genome-Based Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Genome-Based Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Insulin
Table 4. Major Players of Growth Hormone
Table 5. Major Players of Monoclonal Antibody
Table 6. Major Players of Other
Table 7. Global Genome-Based Drug Sales by Type (2018-2023) & (Kiloton)
Table 8. Global Genome-Based Drug Sales Market Share by Type (2018-2023)
Table 9. Global Genome-Based Drug Revenue by Type (2018-2023) & ($ million)
Table 10. Global Genome-Based Drug Revenue Market Share by Type (2018-2023)
Table 11. Global Genome-Based Drug Sale Price by Type (2018-2023) & (US$/Ton)
Table 12. Global Genome-Based Drug Sales by Application (2018-2023) & (Kiloton)
Table 13. Global Genome-Based Drug Sales Market Share by Application (2018-2023)
Table 14. Global Genome-Based Drug Revenue by Application (2018-2023)
Table 15. Global Genome-Based Drug Revenue Market Share by Application (2018-2023)
Table 16. Global Genome-Based Drug Sale Price by Application (2018-2023) & (US$/Ton)
Table 17. Global Genome-Based Drug Sales by Company (2018-2023) & (Kiloton)
Table 18. Global Genome-Based Drug Sales Market Share by Company (2018-2023)
Table 19. Global Genome-Based Drug Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Genome-Based Drug Revenue Market Share by Company (2018-2023)
Table 21. Global Genome-Based Drug Sale Price by Company (2018-2023) & (US$/Ton)
Table 22. Key Manufacturers Genome-Based Drug Producing Area Distribution and Sales Area
Table 23. Players Genome-Based Drug Products Offered
Table 24. Genome-Based Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Genome-Based Drug Sales by Geographic Region (2018-2023) & (Kiloton)
Table 28. Global Genome-Based Drug Sales Market Share Geographic Region (2018-2023)
Table 29. Global Genome-Based Drug Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Genome-Based Drug Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Genome-Based Drug Sales by Country/Region (2018-2023) & (Kiloton)
Table 32. Global Genome-Based Drug Sales Market Share by Country/Region (2018-2023)
Table 33. Global Genome-Based Drug Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Genome-Based Drug Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Genome-Based Drug Sales by Country (2018-2023) & (Kiloton)
Table 36. Americas Genome-Based Drug Sales Market Share by Country (2018-2023)
Table 37. Americas Genome-Based Drug Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Genome-Based Drug Revenue Market Share by Country (2018-2023)
Table 39. Americas Genome-Based Drug Sales by Type (2018-2023) & (Kiloton)
Table 40. Americas Genome-Based Drug Sales by Application (2018-2023) & (Kiloton)
Table 41. APAC Genome-Based Drug Sales by Region (2018-2023) & (Kiloton)
Table 42. APAC Genome-Based Drug Sales Market Share by Region (2018-2023)
Table 43. APAC Genome-Based Drug Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Genome-Based Drug Revenue Market Share by Region (2018-2023)
Table 45. APAC Genome-Based Drug Sales by Type (2018-2023) & (Kiloton)
Table 46. APAC Genome-Based Drug Sales by Application (2018-2023) & (Kiloton)
Table 47. Europe Genome-Based Drug Sales by Country (2018-2023) & (Kiloton)
Table 48. Europe Genome-Based Drug Sales Market Share by Country (2018-2023)
Table 49. Europe Genome-Based Drug Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Genome-Based Drug Revenue Market Share by Country (2018-2023)
Table 51. Europe Genome-Based Drug Sales by Type (2018-2023) & (Kiloton)
Table 52. Europe Genome-Based Drug Sales by Application (2018-2023) & (Kiloton)
Table 53. Middle East & Africa Genome-Based Drug Sales by Country (2018-2023) & (Kiloton)
Table 54. Middle East & Africa Genome-Based Drug Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Genome-Based Drug Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Genome-Based Drug Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Genome-Based Drug Sales by Type (2018-2023) & (Kiloton)
Table 58. Middle East & Africa Genome-Based Drug Sales by Application (2018-2023) & (Kiloton)
Table 59. Key Market Drivers & Growth Opportunities of Genome-Based Drug
Table 60. Key Market Challenges & Risks of Genome-Based Drug
Table 61. Key Industry Trends of Genome-Based Drug
Table 62. Genome-Based Drug Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Genome-Based Drug Distributors List
Table 65. Genome-Based Drug Customer List
Table 66. Global Genome-Based Drug Sales Forecast by Region (2024-2029) & (Kiloton)
Table 67. Global Genome-Based Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Genome-Based Drug Sales Forecast by Country (2024-2029) & (Kiloton)
Table 69. Americas Genome-Based Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Genome-Based Drug Sales Forecast by Region (2024-2029) & (Kiloton)
Table 71. APAC Genome-Based Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Genome-Based Drug Sales Forecast by Country (2024-2029) & (Kiloton)
Table 73. Europe Genome-Based Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Genome-Based Drug Sales Forecast by Country (2024-2029) & (Kiloton)
Table 75. Middle East & Africa Genome-Based Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Genome-Based Drug Sales Forecast by Type (2024-2029) & (Kiloton)
Table 77. Global Genome-Based Drug Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Genome-Based Drug Sales Forecast by Application (2024-2029) & (Kiloton)
Table 79. Global Genome-Based Drug Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Sandoz International Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. Sandoz International Genome-Based Drug Product Portfolios and Specifications
Table 82. Sandoz International Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 83. Sandoz International Main Business
Table 84. Sandoz International Latest Developments
Table 85. Teva pharmaceutical industries Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. Teva pharmaceutical industries Genome-Based Drug Product Portfolios and Specifications
Table 87. Teva pharmaceutical industries Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 88. Teva pharmaceutical industries Main Business
Table 89. Teva pharmaceutical industries Latest Developments
Table 90. Mylan Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. Mylan Genome-Based Drug Product Portfolios and Specifications
Table 92. Mylan Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 93. Mylan Main Business
Table 94. Mylan Latest Developments
Table 95. 3SBio Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. 3SBio Genome-Based Drug Product Portfolios and Specifications
Table 97. 3SBio Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 98. 3SBio Main Business
Table 99. 3SBio Latest Developments
Table 100. Shanghai Fosun Pharmaceutical Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. Shanghai Fosun Pharmaceutical Genome-Based Drug Product Portfolios and Specifications
Table 102. Shanghai Fosun Pharmaceutical Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 103. Shanghai Fosun Pharmaceutical Main Business
Table 104. Shanghai Fosun Pharmaceutical Latest Developments
Table 105. Tonghua Dongbao Pharmaceutical Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. Tonghua Dongbao Pharmaceutical Genome-Based Drug Product Portfolios and Specifications
Table 107. Tonghua Dongbao Pharmaceutical Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 108. Tonghua Dongbao Pharmaceutical Main Business
Table 109. Tonghua Dongbao Pharmaceutical Latest Developments
Table 110. Biocon Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Biocon Genome-Based Drug Product Portfolios and Specifications
Table 112. Biocon Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 113. Biocon Main Business
Table 114. Biocon Latest Developments
Table 115. Reliance Life Sciences Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. Reliance Life Sciences Genome-Based Drug Product Portfolios and Specifications
Table 117. Reliance Life Sciences Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 118. Reliance Life Sciences Main Business
Table 119. Reliance Life Sciences Latest Developments
Table 120. Probiomed Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 121. Probiomed Genome-Based Drug Product Portfolios and Specifications
Table 122. Probiomed Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 123. Probiomed Main Business
Table 124. Probiomed Latest Developments
Table 125. Biosidus Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 126. Biosidus Genome-Based Drug Product Portfolios and Specifications
Table 127. Biosidus Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 128. Biosidus Main Business
Table 129. Biosidus Latest Developments
Table 130. AMEGA Biotech Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 131. AMEGA Biotech Genome-Based Drug Product Portfolios and Specifications
Table 132. AMEGA Biotech Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 133. AMEGA Biotech Main Business
Table 134. AMEGA Biotech Latest Developments
Table 135. Celltrion Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 136. Celltrion Genome-Based Drug Product Portfolios and Specifications
Table 137. Celltrion Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 138. Celltrion Main Business
Table 139. Celltrion Latest Developments
Table 140. LG Life Science Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 141. LG Life Science Genome-Based Drug Product Portfolios and Specifications
Table 142. LG Life Science Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 143. LG Life Science Main Business
Table 144. LG Life Science Latest Developments
Table 145. Dong-A Pharmaceutical Basic Information, Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 146. Dong-A Pharmaceutical Genome-Based Drug Product Portfolios and Specifications
Table 147. Dong-A Pharmaceutical Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 148. Dong-A Pharmaceutical Main Business
Table 149. Dong-A Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Genome-Based Drug
Figure 2. Genome-Based Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Genome-Based Drug Sales Growth Rate 2018-2029 (Kiloton)
Figure 7. Global Genome-Based Drug Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Genome-Based Drug Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Insulin
Figure 10. Product Picture of Growth Hormone
Figure 11. Product Picture of Monoclonal Antibody
Figure 12. Product Picture of Other
Figure 13. Global Genome-Based Drug Sales Market Share by Type in 2022
Figure 14. Global Genome-Based Drug Revenue Market Share by Type (2018-2023)
Figure 15. Genome-Based Drug Consumed in Hospital
Figure 16. Global Genome-Based Drug Market: Hospital (2018-2023) & (Kiloton)
Figure 17. Genome-Based Drug Consumed in Pharmaceutical Factory
Figure 18. Global Genome-Based Drug Market: Pharmaceutical Factory (2018-2023) & (Kiloton)
Figure 19. Genome-Based Drug Consumed in Other
Figure 20. Global Genome-Based Drug Market: Other (2018-2023) & (Kiloton)
Figure 21. Global Genome-Based Drug Sales Market Share by Application (2022)
Figure 22. Global Genome-Based Drug Revenue Market Share by Application in 2022
Figure 23. Genome-Based Drug Sales Market by Company in 2022 (Kiloton)
Figure 24. Global Genome-Based Drug Sales Market Share by Company in 2022
Figure 25. Genome-Based Drug Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Genome-Based Drug Revenue Market Share by Company in 2022
Figure 27. Global Genome-Based Drug Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Genome-Based Drug Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Genome-Based Drug Sales 2018-2023 (Kiloton)
Figure 30. Americas Genome-Based Drug Revenue 2018-2023 ($ Millions)
Figure 31. APAC Genome-Based Drug Sales 2018-2023 (Kiloton)
Figure 32. APAC Genome-Based Drug Revenue 2018-2023 ($ Millions)
Figure 33. Europe Genome-Based Drug Sales 2018-2023 (Kiloton)
Figure 34. Europe Genome-Based Drug Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Genome-Based Drug Sales 2018-2023 (Kiloton)
Figure 36. Middle East & Africa Genome-Based Drug Revenue 2018-2023 ($ Millions)
Figure 37. Americas Genome-Based Drug Sales Market Share by Country in 2022
Figure 38. Americas Genome-Based Drug Revenue Market Share by Country in 2022
Figure 39. Americas Genome-Based Drug Sales Market Share by Type (2018-2023)
Figure 40. Americas Genome-Based Drug Sales Market Share by Application (2018-2023)
Figure 41. United States Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Genome-Based Drug Sales Market Share by Region in 2022
Figure 46. APAC Genome-Based Drug Revenue Market Share by Regions in 2022
Figure 47. APAC Genome-Based Drug Sales Market Share by Type (2018-2023)
Figure 48. APAC Genome-Based Drug Sales Market Share by Application (2018-2023)
Figure 49. China Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Genome-Based Drug Sales Market Share by Country in 2022
Figure 57. Europe Genome-Based Drug Revenue Market Share by Country in 2022
Figure 58. Europe Genome-Based Drug Sales Market Share by Type (2018-2023)
Figure 59. Europe Genome-Based Drug Sales Market Share by Application (2018-2023)
Figure 60. Germany Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Genome-Based Drug Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Genome-Based Drug Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Genome-Based Drug Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Genome-Based Drug Sales Market Share by Application (2018-2023)
Figure 69. Egypt Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Genome-Based Drug in 2022
Figure 75. Manufacturing Process Analysis of Genome-Based Drug
Figure 76. Industry Chain Structure of Genome-Based Drug
Figure 77. Channels of Distribution
Figure 78. Global Genome-Based Drug Sales Market Forecast by Region (2024-2029)
Figure 79. Global Genome-Based Drug Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Genome-Based Drug Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Genome-Based Drug Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Genome-Based Drug Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Genome-Based Drug Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Genome-Based Drug
Figure 2. Genome-Based Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Genome-Based Drug Sales Growth Rate 2018-2029 (Kiloton)
Figure 7. Global Genome-Based Drug Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Genome-Based Drug Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Insulin
Figure 10. Product Picture of Growth Hormone
Figure 11. Product Picture of Monoclonal Antibody
Figure 12. Product Picture of Other
Figure 13. Global Genome-Based Drug Sales Market Share by Type in 2022
Figure 14. Global Genome-Based Drug Revenue Market Share by Type (2018-2023)
Figure 15. Genome-Based Drug Consumed in Hospital
Figure 16. Global Genome-Based Drug Market: Hospital (2018-2023) & (Kiloton)
Figure 17. Genome-Based Drug Consumed in Pharmaceutical Factory
Figure 18. Global Genome-Based Drug Market: Pharmaceutical Factory (2018-2023) & (Kiloton)
Figure 19. Genome-Based Drug Consumed in Other
Figure 20. Global Genome-Based Drug Market: Other (2018-2023) & (Kiloton)
Figure 21. Global Genome-Based Drug Sales Market Share by Application (2022)
Figure 22. Global Genome-Based Drug Revenue Market Share by Application in 2022
Figure 23. Genome-Based Drug Sales Market by Company in 2022 (Kiloton)
Figure 24. Global Genome-Based Drug Sales Market Share by Company in 2022
Figure 25. Genome-Based Drug Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Genome-Based Drug Revenue Market Share by Company in 2022
Figure 27. Global Genome-Based Drug Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Genome-Based Drug Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Genome-Based Drug Sales 2018-2023 (Kiloton)
Figure 30. Americas Genome-Based Drug Revenue 2018-2023 ($ Millions)
Figure 31. APAC Genome-Based Drug Sales 2018-2023 (Kiloton)
Figure 32. APAC Genome-Based Drug Revenue 2018-2023 ($ Millions)
Figure 33. Europe Genome-Based Drug Sales 2018-2023 (Kiloton)
Figure 34. Europe Genome-Based Drug Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Genome-Based Drug Sales 2018-2023 (Kiloton)
Figure 36. Middle East & Africa Genome-Based Drug Revenue 2018-2023 ($ Millions)
Figure 37. Americas Genome-Based Drug Sales Market Share by Country in 2022
Figure 38. Americas Genome-Based Drug Revenue Market Share by Country in 2022
Figure 39. Americas Genome-Based Drug Sales Market Share by Type (2018-2023)
Figure 40. Americas Genome-Based Drug Sales Market Share by Application (2018-2023)
Figure 41. United States Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Genome-Based Drug Sales Market Share by Region in 2022
Figure 46. APAC Genome-Based Drug Revenue Market Share by Regions in 2022
Figure 47. APAC Genome-Based Drug Sales Market Share by Type (2018-2023)
Figure 48. APAC Genome-Based Drug Sales Market Share by Application (2018-2023)
Figure 49. China Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Genome-Based Drug Sales Market Share by Country in 2022
Figure 57. Europe Genome-Based Drug Revenue Market Share by Country in 2022
Figure 58. Europe Genome-Based Drug Sales Market Share by Type (2018-2023)
Figure 59. Europe Genome-Based Drug Sales Market Share by Application (2018-2023)
Figure 60. Germany Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Genome-Based Drug Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Genome-Based Drug Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Genome-Based Drug Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Genome-Based Drug Sales Market Share by Application (2018-2023)
Figure 69. Egypt Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Genome-Based Drug Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Genome-Based Drug in 2022
Figure 75. Manufacturing Process Analysis of Genome-Based Drug
Figure 76. Industry Chain Structure of Genome-Based Drug
Figure 77. Channels of Distribution
Figure 78. Global Genome-Based Drug Sales Market Forecast by Region (2024-2029)
Figure 79. Global Genome-Based Drug Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Genome-Based Drug Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Genome-Based Drug Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Genome-Based Drug Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Genome-Based Drug Revenue Market Share Forecast by Application (2024-2029)
